BYOT Byotrol Plc

    Byotrol plc

Byotrol plc ("the Company"), the AIM-quoted anti-microbial technology business
has succeeded in obtaining approvals from the Environment Protection Agency
("EPA") in the United States for its technology to be used as a disinfectant,
sanitiser and anti-microbial product.

As part of this process, the EPA has approved the Company's claims that its
technology is effective against a range of micro-organisms including Salmonella,
Listeria, MRSA, E.coli and Avian Influenza.

The EPA is the legislative body in the USA which is responsible for protecting
human health and the environment. It regulates the approval of new technologies
and products for use in these areas, and the performance claims that can legally
be made on the product labels.

The approvals follow a 7 month review process undertaken by the EPA and allows
Byotrol to market disinfectants and sanitisers in the USA in the Company's
initially targeted markets in healthcare, food and industrial technology. As set
out in the Admission Document at the time of the AIM flotation, the EPA
registration represents an important milestone in the Company's commercial
strategy.

The approvals allow the Company to market its products in concentrate form as a
sanitiser and disinfectant for domestic use and for customers including
hospitals and other healthcare institutions, food processing plants and
agricultural facilities (including those subject to inspection by the US
Department of Agriculture), restaurants, retail operations, hotels, public
transport facilities, schools and universities, health clubs and spas.

The Company has identified significant demand for its products in these areas
based on discussions with a number of potential customers who have, until now,
been unable to trial or acquire Byotrol's products without the EPA approvals
that have now been obtained.

This latest clearance for Byotrol's technology comes days after the Company was
awarded CE Mark status for its products which allows it to market its technology
to the medical sector on a pan European basis.

Byotrol's Deputy Chairman Stephen Falder commented: "The EPA acceptance of our
anti-microbial claims is a very important springboard for key market sectors in
the USA. We had originally anticipated that, at this stage, we would receive EPA
acceptance for 5 to 7 market-specific claims but I am delighted to say that we
have been able to obtain in excess of 20 approvals. Each approval allows us to
sell our product in concentrate form to customers in a particular category or
market sector. This is considerably ahead of our plan and a significant step
forward for the Company following the detailed and complex work of the
registration process."

According to the Global Biocides Report, the worldwide biocide market was valued
in excess of $5.9 billion in 2005, with the USA the largest user of biocides,
and is currently growing at around 4% per annum.

According to David McRobbie, Chief Executive Officer of Byotrol plc, "EPA
approval is one of the most significant milestones in the Company's development
to date. The approval, which was achieved on time and within budget, opens up
the vast United States market for our technology and allows us to sell our
products into a broader spectrum of sectors than we had originally anticipated.
This builds on our progress in the UK and Europe where we have started to sell
our products in a broad range of markets, from care homes and medical
laboratories through to food processing and industrial coatings."


Financial calls to:

Stephen Falder
Byotrol plc
0870 609 4480

Or

Oli Rayner
Merchant Capital
0207 332 2200

Media calls to:

Jim Rothnie
McCann Erickson PR
T: 01625 822540
E: jim.rothnie@europe.mccann.com

Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Lug 2023 a Lug 2024